According to the Market Statsville Group (MSG), the global nomegestrol acetate drugs market size is expected to grow from USD XX million in 2022 to USD XX million by 2033, growing at a CAGR of XX% from 2023 to 2033. The increasing gynecological disorders among the adult and teenage such as (menstrual disturbances, dysmenorrhea, premenstrual syndrome) has boosted the market growth over the forecasting period in all over the world. Moreover, many European government and other government is approving this drug in treatment of menopausal syndrome, uterine diseases, and menorrhagia, and in combination with an estrogen for the treatment of menopausal symptoms will create growth opportunities for the new and existing market player to capture the market over the forecasting period in all around the globe. An unhealthy and stressful lifestyle has also contributed the market growth over the forecasted period. However, the adverse effects and overdose of this drug has restricted the market growth over the forecast period.
Nomegestrol acetate (NOMAC), also known as Lutenyl and Zoely, is a progestin drug used in birth control pills, menopausal hormone therapy, and the treatment of gynecological problems. It is available alone as well as in conjunction with estrogen. NOMAC is administered orally. Since NOMAC is processed by the liver, hepatic dysfunction may result in a buildup of the medicine. NOMAC metabolism is dependent on CYP3A4, inhibitors and inducers of this enzyme, such as ketoconazole and rifampicin, as well as several anticonvulsants, may have a clinically relevant pharmacological interaction with NOMAC. NOMAC also possesses progestogenic, antigonadotrophic, and antiandrogenic actions, but there is no other significant hormonal activity presented on it.
While the pandemic has caused supply chain disruptions and decreased access to healthcare services in some locations, it has also raised demand for nomegestrol acetate medications in some areas. The pandemic has caused interruptions in nomegestrol acetate medicine manufacturing and supply, particularly in nations where production facilities have been disrupted by lockdowns or decreased capacity owing to social distancing measures. In addition, because of the COVID-19 pandemic, the healthcare sector has experienced a shift in tendencies towards healthcare rather than inpatient treatment. In the next years, the trend towards healthcare services is likely to raise demand for nomegestrol acetate drugs.
NOMAC is used alone to treat gynaecological problems such as monthly irregularities (e.g., dysmenorrhea, menorrhagia, oligomenorrhea, polymenorrhagia, amenorrhea), vaginal bleeding, breast discomfort, and premenstrual syndrome, as well as menopausal hormone therapy. Due to increasing unhealthy lifestyle among the younger people around the world had created lots of gynaecological disorders patients and this has boosted the market growth over the forecast period. Increasing unhealthy lifestyles are a global concern. Due to hectic life pressure and busy schedule of people are causing unhealthy lifestyle among the people. This unhealthy lifestyle has increased the chances of gynaecological disorder among the women.
Every drug has its own unwanted undesirable effects that are possibly related to a drug. NOMAC's negative effects are comparable to those of other progestogens. It is easily tolerated and frequently has adverse effects. Menstrual abnormalities (e.g., abnormal bleeding or spotting), headache, nausea, breast tenderness, and weight gain are all possible adverse effects of NOMAC. Breast tenderness, urine discoloration, sleepiness, profuse vaginal bleeding (2-7 days after the overdose), headache, mood changes, nausea, vomiting, and rash are also mild clinical indications of an overdose. NOMAC and estradiol overdose symptoms may include nausea, vomiting, and, in young females, minor vaginal bleeding. There is no antidote for NOMAC overdose, and overdose management should be based on symptoms. This has hampered market growth over the forecasting period.
Hormone replacement therapy (HRT) is a treatment to relieve symptoms of the menopause. Increase in prevalence of Hormone replacement therapy (HRT) in all over the world is create growth opportunities for the new and existing market player over the forecasting period. Hormone Replacement Therapy (HRT) replenishes the feminine hormones that are reduced after menopause. Female hormones oestrogen and progesterone perform significant roles in a woman's biology. Moreover, the government approving has also boosted the market growth over the forecast period. For instance, a similar chemical, nomegestrol, was patented in 1975, and NOMAC was characterised in 1983. NOMAC was initially approved for medical use in Europe in 1986 for the treatment of gynaecological problems and menopausal hormone therapy. It was later authorised as a component of birth control tablets in Europe in 2011. NOMAC is widely distributed across the world. It cannot be obtained in the United States or Canada.
The study categorizes the nomegestrol acetate drugs market based on type, and end user area at the regional and global levels.
Based on the type, the market is divided into menstrual disturbances, dysmenorrhea, premenstrual syndrome. The menstrual disturbances segment is expected to dominate the market share in 2022 in the global nomegestrol acetate drugs market. The menstrual disturbances segment currently dominates the market share in the nomegestrol acetate drugs market. Menstrual disorders are issues that interfere with a woman's regular menstrual cycle. These include intense cramping during menstruation, very excessive flow, or no bleeding at all. The increasing menstrual disturbances among the adults and unhealthy lifestyle has boost this segment and registered the largest market share over the forecast period.
Based on the regions, the global nomegestrol acetate drugs market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. North America is projected to account for the highest market share in 2022. Favorable healthcare regulations, the rise of big data in the healthcare business, and technological improvements are boosting market expansion in the North American healthcare analytics market. Another location driving the healthcare analytics market is the region's favorable healthcare policies. Moreover, a scarcity of medical personnel, an ageing population, and an increase in the frequency of chronic illnesses such as diabetes, cancer, and Cardiovascular Diseases (CVDs) are likely to drive the market in this area.
The nomegestrol acetate drugs market is a significant competitor, and extremely cutthroat in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.
Frequently Asked Questions
Want to Review Complete Market Research Report
Budget constraints? Get in touch with us for special pricing
Request for Special PricingCustomize this Report
Related Reports
Metagenomics Sequencing Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Medical Cannabis Oil Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Novel Vaccine Delivery System Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Lysosomal Storage Disease Treatment Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Single-Use Bioprocessing Market 2022: Industry Size, Emerging Trends, Regions, Growth Insights, Opportunities, and Forecast By 2033
Mar 2024